153 patents
Page 4 of 8
Utility
Modified Mrna for the Treatment of Progressive Familial Intrahepatic Cholestasis Disorders
24 Feb 22
The present disclosure provides compositions of nucleic acids relating to biliary epithelial transporters.
Paolo Martini, Vladimir Presnyak, Jingsong CAO
Filed: 13 Sep 19
Utility
High-purity Peg Lipids and Uses Thereof
3 Feb 22
The present disclosure is based, at least in part, on the discovery that high-purity PEG lipids exhibit superior physical and biological properties, particularly when used in lipid nanoparticle (LNP) formulations.
Örn Almarsson, Jin Lim, Eugene Cheung, Jaclyn Milton
Filed: 19 Sep 19
Utility
CorrectedInfluenza Vaccine
27 Jan 22
The invention relates to compositions and methods for the preparation, manufacture and therapeutic use ribonucleic acid vaccines comprising polynucleotide molecules encoding one or more influenza antigens, such as hemagglutinin antigens.
Giuseppe Ciaramella
Filed: 18 Dec 20
Utility
Use of Mrna Encoding OX40L to Treat Cancer In Human Patients
6 Jan 22
The disclosure features methods for treating ovarian cancer, as well as other cancers such as solid tumors, lymphomas and epithelial origin cancers, by administering mRNA encoding an OX40L polypeptide.
Robert MEEHAN, Sima ZACHAREK, Kristen HOPSON, Joshua P. FREDERICK
Filed: 8 Nov 19
Utility
Rna Polymerase Variants
23 Dec 21
The present disclosure provides, in some aspects, variant RNA polymerases, the use of which increases transcription efficiency while reducing the number of double-stranded RNA contaminates and run-on transcripts produced during an in vitro transcription reaction.
Amy E. Rabideau, Athanasios Dousis, Kanchana Ravichandran, Elissa Hobert
Filed: 17 Jun 21
Utility
Delivery and Formulation of Engineered Nucleic Acids
16 Dec 21
Provided are formulations, compositions and methods for delivering biological moieties such as modified nucleic acids into cells to modulate protein expression.
Antonin DE FOUGEROLLES, Sayda M. ELBASHIR
Filed: 5 Jan 21
Utility
Preparation of Lipid Nanoparticles and Methods of Administration Thereof
9 Dec 21
The present disclosure provides methods of producing lipid nanoparticle (LNP) formulations and the produced LNP formulations thereof.
Allen HORHOTA, Christopher Karl MCLAUGHLIN, Jessica CHENEY, Ben GELDHOF, Jeffrey HRKACH, Melissa J. MOORE, Stephen G. HOGE
Filed: 20 Sep 19
Utility
Delivery of Dna
11 Nov 21
The compositions and methods described herein relate to lipid nanoparticle encapsulation of DNA sequences, including DNA vectors, for delivery into a human subject.
Stoil Dimitrov, Eric Huang
Filed: 21 May 19
Utility
Sterol Purification
11 Nov 21
The invention relates to sterol esters and methods for producing purified sterols that can be utilized in methods for producing a lipid nanoparticle.
Gabor BUTORA, Jin LIM, Gary SHEN, Alison VOLKERT
Filed: 19 Sep 19
Utility
Methods of Using OX40 Ligand Encoding Polynucleotides
14 Oct 21
The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotide molecules comprising an mRNA encoding an OX40L polypeptide.
Joshua P. FREDERICK, Ailin BAI
Filed: 16 Mar 21
Utility
Modified Nucleosides, Nucleotides, and Nucleic Acids, and Uses Thereof
7 Oct 21
The present disclosure provides modified nucleosides, nucleotides, and nucleic acids, and methods of using them.
Antonin DE FOUGEROLLES, Atanu ROY
Filed: 25 Sep 20
Utility
Rna Polymerase Variants for Co-transcriptional Capping
7 Oct 21
The present disclosure provides RNA polymerase variants for high efficiency transcription.
Athanasios Dousis, Kanchana Ravichandran, Amy E. Rabideau, Margaret Franklin, Kevin Smith
Filed: 20 May 21
Utility
Polynucleotides Encoding INTERLEUKIN-12 (IL12) and Uses Thereof
30 Sep 21
The present disclosure relates to polynucleotides comprising an open reading frame of linked nucleosides encoding human interleukin-12 (IL12), functional fragments thereof, and fusion proteins comprising IL12.
Joshua FREDERICK, Susannah HEWITT, Ailin BAI, Stephen HOGE, Vladimir PRESNYAK, Iain MCFADYEN, Kerry BENENATO, Ellalahewage Sathyajith KUMARASINGHE
Filed: 5 May 21
Utility
Modified Polynucleotides for the Production of Biologics and Proteins Associated with Human Disease
30 Sep 21
The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.
Stephane BANCEL, Tirtha CHAKRABORTY, Antonin DE FOUGEROLLES, Sayda M. ELBASHIR, Matthias JOHN, Atanu ROY, Susan WHORISKEY, Kristy M. WOOD, Paul HATALA, Jason P. SCHRUM, Kenechi EJEBE, Jeff Lynn ELLSWORTH, Justin GUILD
Filed: 14 Sep 20
Utility
Personalized Cancer Vaccine Epitope Selection
2 Sep 21
The disclosure relates to optimized cancer vaccines, as well as methods of making the vaccines, using the vaccines, and compositions comprising the vaccines.
Shan Zhong, Benjamin Breton, Iain Mcfadyen, Kristen Hopson, Vincent Luczkow, Maija Garnaas
Filed: 27 Jun 19
Utility
Polynucleotides Encoding Immune Modulating Polypeptides
2 Sep 21
The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotide molecules encoding at least one polypeptide of interest to modulate the immune response.
Joseph Beene BOLEN, Joshua P. FREDERICK
Filed: 21 Sep 20
Utility
Polynucleotides Encoding GALACTOSE-1-PHOSPHATE Uridylyltransferase for the Treatment of Galactosemia Type 1
2 Sep 21
The invention relates to mRNA therapy for the treatment of galactosemia type 1 (Gal-1). mRNAs for use in the invention, when administered in vivo, encode human galactose-1-phosphate uridylyltransferase (GALT), isoforms thereof, functional fragments thereof, and fusion proteins comprising GALT. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of GALT expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient GALT activity in subjects, namely galactose-1-phosphate (Gal-1-P).
Paolo Martini, Stephen Hoge, Kerry Benenato, Vladimir Presnyak, Iain McFadyen, Ellalahewage Sathyajith Kumarasinghe, Ding An, Staci Sabnis
Filed: 21 Jan 21
Utility
Methods for Therapeutic Administration of Messenger Ribonucleic Acid Drugs
26 Aug 21
The disclosure features methods of reducing or inhibiting an anti-drug antibody response in a subject, as well as methods of reducing or inhibiting unwanted immune cell activation in a subject to be treated with a messenger RNA (mRNA), comprising administering to the subject a mRNA, e.g., a chemically modified messenger RNA (mmRNA), encoding a polypeptide of interest, wherein the mRNA comprises at least one microRNA (miR) binding site for a miR expressed in immune cells, such as miR-126 binding site and/or miR-142 binding site, such that an anti-drug antibody response to the polypeptide or interest, or unwanted immune cell activation (e.g., B cell activation, cytokine secretion), is reduced or inhibited in the subject.
Stephen HOGE, Tirtha CHAKRABORTY, Gilles BESIN, Ruchi JAIN
Filed: 29 Sep 20
Utility
Zoonotic Disease Rna Vaccines
19 Aug 21
The disclosure relates to Lassa virus, Nipah virus, and betacoronavirus ribonucleic acid vaccines as well as methods of using the vaccines and compositions comprising the vaccines.
Giuseppe Ciaramella, Sunny Himansu, Vladimir Presnyak, Kerry Benenato, Ellalahewage Sathyajith Kumarasinghe
Filed: 22 Jan 21
Utility
Engineered Nucleic Acids and Methods of Use Thereof
5 Aug 21
Provided are compositions and methods for delivering biological moieties such as modified nucleic acids into cells to modulate protein expression.
Jason P. Schrum, Gregory J. Sieczkiewicz, Kenechi Ejebe, Sayda M. Elbashir
Filed: 16 Jul 20